Inc. (AMEX: ISR), announced today a new dual therapy study using
(internal radiation therapy) and external beam radiation.
Multiple sites have now received
Institutional Review Board (IRB) approval for this study which will examine the efficacy of combining intensity modulated radiation (IMRT)
with Cesium-131 brachytherapy to treat intermediate and high risk early stage prostate cancer.
Published studies have suggested that the combination of brachytherapy and external beam radiation treatments demonstrate a significant benefit for those patients at risk of failure due to significant cancer that has spread outside the prostate.
Cesium-131 has been so successful as a sole therapy for low and intermediate prostate cancers that many physicians are interested in its use in conjunction with other treatments like external beam radiation therapy for cases that are at high risk of failure.
The study is expected to demonstrate that the partnership of these two therapies will enhance treatment by lowering the required dosage of both applications resulting in improved outcomes for high risk cases and potentially lessening side effects normally associated with prostate cancer treatments.
The study will also evaluate PSA response and its return to baseline or normal levels. PSA is a protein produced in the prostate. High levels of PSA typically indicate the presence of prostate cancer.
The two key primary investigators are Dr. John Sylvester, Lakewood Ranch Oncology Center in Florida, and Dr. Brian Moran, Director of the Chicago Prostate Center.
Dr Sylvester, a nationally recognized expert who is one of the three clinicians who wrote the most recent ABS (American Brachytherapy Society) guidelines used by prostate cancer brachytherapists worldwide, says," The Cesium-131 monotherapy trial we participated in has published* a 98% success rate in early stage cancer patients. We are excited about this new protocol for intermediate and high risk patients. We expect excellent cancer free survival rates and even less urinary side effects than past combination therapy protocols
Dr. Moran, also an author of the monotherapy study, is recognized nationwide as an expert on brachytherapy and prostate cancer. Dr. Moran has high expectations for the dual therapy study. "We have already seen exceptional results using Cesium-131 as a monotherapy. Given its importance in providing improved outcomes for patients, we expect this study will yield exciting results in a dual therapy setting," he said.
One in six men will be diagnosed with prostate cancer during their lifetimes. It is the second leading cause of cancer deaths among American men claiming more than 30,000 lives annually.
Only lung cancer claims the lives of more men each year.
IsoRay CEO Dwight Babcock says the study represents another important step forward. "Cesium-131 is already demonstrating its vital role in fighting early and intermediate stage prostate cancers. Cesium-131's full potential in aggressively treating cancers throughout the body has yet to be realized.
We expect this study will add to the growing body of evidence demonstrating Cesium-131's vital role as an effective treatment with important quality of life benefits," he explained.
IsoRay is the exclusive manufacturer of Cesium-131.
The pioneering brachytherapy treatment represents one of the most important advancements in internal radiation therapy in 20 years.
Cesium-131 allows for the internal radiation treatment of many different cancers because of its unique combination of high energy (its distinctive tissue penetrating capability reaching just far enough to treat the cancer) and its 9.7 day half-life (its matchless speed in giving off therapeutic radiation). The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and mesh, and several new implantable devices
In addition to its CMS codes, Cesium-131 is FDA-cleared for the treatment of
brain, breast, colorectal, and head and neck
as other cancers throughout the body.
*Abstract published in Brachytherapy, Volume 10, Supplement 1, S27 - S28, 2011.